Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib

Introduction Our patient treated with pembrolizumab and axitinib is one of the longest survivors in Japan on KEYNOTE 426, despite adverse events, including delayed‐onset hepatitis. We herein present a detailed clinical course and short discussion on the case. Case presentation This was a 49‐year‐old...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Koshiro Nishimoto, Suguru Shirotake, Yu Miyama, Go Kaneko, Kent Kanao, Daisuke Igarashi, Takayuki Takahashi, Yuta Umezawa, Masanori Yasuda, Masafumi Oyama
Формат: Artigo
Язык:Inglês
Опубликовано: Wiley 2022-05-01
Серии:IJU Case Reports
Предметы:
axitinib
KEYNOTE426
metastatic renal cell carcinoma
pembrolizumab
Online-ссылка:https://doi.org/10.1002/iju5.12422
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы